Why Is Acyclovir Given to Cancer Patients?

Acyclovir is given to cancer patients primarily to prevent reactivation of herpes viruses, especially herpes simplex virus (HSV) and varicella zoster virus (VZV, the virus behind chickenpox and shingles). Cancer treatments like chemotherapy, radiation, and stem cell transplantation suppress the immune system so severely that dormant herpes viruses already living in a patient’s nerve cells can wake up and cause painful, sometimes dangerous infections. Acyclovir works as a prophylactic shield during these vulnerable windows, and the evidence behind this practice is strong enough that major oncology guidelines now recommend it as standard care for specific patient groups.

Why Cancer Patients Are So Vulnerable to Herpes Viruses

Most adults carry at least one herpes virus. After an initial infection, these viruses don’t leave the body. They retreat into nerve cells and stay dormant, held in check by the immune system. In a healthy person, the virus may never cause problems again, or it might flare up occasionally as a cold sore or a mild shingles rash. In a cancer patient, the calculus changes dramatically.

Cancer itself can weaken immune defenses, but the treatments do most of the damage. Chemotherapy drugs kill rapidly dividing cells, which includes the immune cells responsible for keeping herpes viruses dormant. Radiation therapy has similar effects when directed at bone marrow or lymph nodes. The result is that the specific arm of immunity responsible for viral control gets knocked down right when the patient can least afford an infection. Cancer patients face a particularly high risk of complications from these reactivations, including disseminated and visceral infections that spread beyond the skin to internal organs.¹

A classic study of lymphoma patients showed this pattern clearly. Patients treated with both radiation and chemotherapy had the highest incidence of herpes virus reactivation, ranging from about 15 to 19 percent. The duration of immune suppression caused by treatment, rather than anything about the cancer itself, was the most important factor driving these recurrences.²

How Acyclovir Works, and Why It Is Especially Suited to This Job

Acyclovir has an elegant trick that makes it particularly useful in cancer patients who are already dealing with the toxic side effects of chemotherapy. The drug is essentially inactive until a herpes virus activates it. Herpes-infected cells produce an enzyme called viral thymidine kinase, which converts acyclovir into its active form. Uninfected cells barely touch the drug. Once activated inside an infected cell, acyclovir jams the viral machinery that copies DNA, shutting down viral replication. The active form of the drug inhibits the viral DNA-copying enzyme far more powerfully than it affects the equivalent human enzymes.³

This selectivity matters enormously in oncology. Cancer patients on chemotherapy already have cells being hammered by toxic drugs. Adding another medication that broadly damages human cells would compound the problem. Acyclovir’s design means it concentrates its effects almost entirely in virus-infected cells, leaving healthy tissue largely alone. For Epstein-Barr virus (EBV), a related herpes virus, the active form of acyclovir has roughly 100 times more affinity for the viral polymerase than for the host cell’s own DNA-copying machinery.⁴

Which Cancer Patients Receive Acyclovir Prophylaxis

Not every cancer patient gets acyclovir. The decision follows the intensity of immune suppression and the type of cancer treatment involved. The strongest evidence and clearest guidelines center on two groups: patients undergoing stem cell transplantation and patients with blood cancers receiving intensive chemotherapy.

Herpes simplex stomatitis, which causes severe, painful mouth sores, occurs frequently in patients with acute leukemia treated with intensive chemotherapy. Herpes zoster (shingles) is particularly common in patients with lymphoma or multiple myeloma.⁵ These aren’t minor inconveniences. Mouth sores in a patient with almost no white blood cells can become a gateway for bacterial infections entering the bloodstream. Shingles can disseminate throughout the body and become life-threatening.

The joint guideline from the American Society of Clinical Oncology and the Infectious Diseases Society of America is direct: patients who are seropositive for herpes simplex virus and undergoing either allogeneic stem cell transplantation or leukemia induction therapy should receive acyclovir or a related antiviral as prophylaxis.⁶

For solid tumors like breast, lung, or colon cancer, the picture is more nuanced. Standard chemotherapy for these cancers causes immune suppression, but usually not as profound or prolonged as what leukemia patients endure. German oncology guidelines recommend a risk-adapted approach: patients on certain especially immunosuppressive drugs such as alemtuzumab, bortezomib, or purine analogues should receive acyclovir or its prodrug valacyclovir, regardless of whether the underlying cancer is a blood cancer or a solid tumor.⁷ The key variable is how deeply the treatment suppresses immunity, not the tumor type per se.

The Evidence That Prophylaxis Actually Works

The case for acyclovir prophylaxis rests on decades of clinical trials. Some of the earliest controlled studies were striking. In one placebo-controlled trial involving both bone marrow transplant recipients and patients receiving chemotherapy, half of the patients on placebo developed herpes simplex infections. Among those receiving acyclovir, none of the transplant patients and only about 10 percent of the chemotherapy patients became infected.⁸

A systematic review and meta-analysis that pooled data from multiple trials in hematology patients confirmed these findings at scale. During chemotherapy, acyclovir cut HSV disease significantly, with a number needed to treat of about three, meaning that for every three patients given the drug, one case of herpes disease was prevented. In the pre-engraftment period around stem cell transplantation, the effect was even larger, with a number needed to treat of two.⁹ Those are unusually efficient numbers for a preventive medication. The meta-analysis did note, however, that preventing herpes infections did not translate into a reduction in overall mortality, a finding that underscores the role of acyclovir as a quality-of-life and complication-prevention tool rather than a survival drug.

Stem Cell Transplantation and the Long Prophylaxis Window

Stem cell transplant patients represent the most intensely immunosuppressed group in oncology, and they receive acyclovir for much longer stretches than patients on standard chemotherapy. The immune system essentially has to rebuild from scratch after transplantation, a process that can take a year or more. During that time, varicella zoster virus reactivation is a major concern.

A randomized, placebo-controlled trial of long-term acyclovir after allogeneic stem cell transplantation demonstrated this clearly. Patients received acyclovir from about one to two months after transplantation through the end of the first year. Acyclovir reduced VZV infections dramatically during that year, with a hazard ratio of 0.16, meaning the risk was cut by roughly 84 percent compared to placebo.¹⁰

In children undergoing stem cell transplantation, a similar pattern plays out. A pediatric study found that while only one patient developed VZV reactivation while actively taking acyclovir, the rate climbed sharply after the drug was stopped, reaching about 24 percent within one year of cessation.¹¹ This finding has shaped the ongoing debate about how long prophylaxis should continue. Many transplant centers now keep patients on acyclovir for at least a year, and some extend it even further for patients still on immunosuppressive medications.

Dosing, Routes, and the Valacyclovir Alternative

One practical challenge with acyclovir is that it isn’t absorbed especially well when taken by mouth. In cancer patients with low white blood cell counts after chemotherapy, the oral bioavailability of acyclovir sits around 21 percent, meaning that roughly four-fifths of each dose passes through the gut without reaching the bloodstream.¹² To compensate, patients often need multiple daily doses. Clinical trials have used a range of dosing schedules, from 200 mg four times daily to 800 mg twice daily, depending on the clinical setting and whether the goal is HSV or VZV prevention.

Valacyclovir was developed specifically to address this absorption problem. It’s a prodrug, meaning the body converts it into acyclovir after absorption, but it enters the bloodstream much more efficiently. In the same leukopenic cancer patients, valacyclovir achieved about 70 percent bioavailability, more than three times that of plain acyclovir.¹² This allows fewer daily doses, which matters when a patient may already be taking a dozen or more medications.

Head-to-head comparisons have been reassuring. In a trial comparing acyclovir to two different valacyclovir doses in neutropenic patients, clinical success rates were virtually identical across all three groups, ranging from 95 to 100 percent.¹³ Studies comparing oral valacyclovir to intravenous acyclovir have also found comparable drug levels in the blood, with the oral route actually producing lower peak concentrations. Lower peaks with similar overall exposure may be safer for the kidneys, and the convenience of an oral pill versus an IV infusion can shorten hospital stays.¹⁴

Despite these advantages, many protocols still use acyclovir itself because it has a longer track record, the IV formulation is needed when patients can’t swallow or absorb oral medications, and it’s generally cheaper. In practice, the choice between acyclovir and valacyclovir often comes down to whether the patient can reliably take pills.

Kidney Risks and Other Side Effects

Acyclovir is generally well tolerated, but it does carry a specific risk that oncologists have to watch for: kidney damage. The drug can crystallize in the kidney tubules, especially when a patient is dehydrated or when blood levels climb too high. Cancer patients are often at elevated risk for both of these problems, whether from nausea-induced poor fluid intake, the kidney-toxic effects of other chemotherapy drugs, or the disease itself compromising kidney function.

Patients with multiple myeloma deserve special caution. Myeloma produces abnormal proteins that can directly damage kidney tubules, a condition that makes it easier for acyclovir to accumulate to toxic levels. Case reports have documented acyclovir-induced encephalopathy, a state of confusion, agitation, or altered consciousness, in myeloma patients with impaired kidney function who were receiving what would otherwise be routine preventive doses. The irony is that myeloma patients are among those most in need of antiviral prophylaxis, since bortezomib, a cornerstone of myeloma treatment, strongly predisposes to herpes zoster reactivation.¹⁵ In these patients, careful dose adjustment and monitoring of kidney function and mental status are essential.

What Acyclovir Does Not Cover

A common point of confusion is the assumption that acyclovir protects against all herpes-family viruses. It doesn’t. The drug’s activity is strong against HSV types 1 and 2 and VZV, but it has limited clinical usefulness against cytomegalovirus (CMV) and Epstein-Barr virus (EBV).¹⁶ This matters because CMV reactivation is one of the most dangerous infections after stem cell transplantation, and it requires different antiviral drugs entirely, typically ganciclovir or foscarnet. When a transplant patient is on “antiviral prophylaxis,” they may actually be taking acyclovir for HSV and VZV alongside a separate monitoring or treatment strategy for CMV.

The reason for this gap comes back to acyclovir’s mechanism. CMV does not produce the same type of thymidine kinase that HSV and VZV do, so the critical first activation step is much less efficient. The drug can reach some level of activity against EBV’s polymerase in the lab, as the research on EBV polymerase inhibition showed, but translating that into clinical benefit has proven harder. Oncologists treat CMV and EBV reactivation as separate problems requiring their own targeted drugs.

When the Virus Fights Back

Long-term acyclovir use in immunosuppressed patients creates conditions that favor the emergence of drug-resistant herpes strains. Resistance typically arises from mutations in the viral thymidine kinase gene, the very enzyme acyclovir depends on for activation. If the virus loses or alters that enzyme, acyclovir can no longer get switched on inside the infected cell. This is rare in people with normal immune systems but occurs more often in heavily immunosuppressed cancer patients, particularly those who have been on acyclovir for extended periods after transplantation.

When resistance does develop, it creates a difficult clinical scenario. The standard backup drugs, like foscarnet and cidofovir, are more toxic and harder to administer than acyclovir. Newer agents such as brincidofovir have shown activity against acyclovir-resistant HSV in cancer patients. Brincidofovir works through a different mechanism and has demonstrated roughly 100-fold greater potency than acyclovir for inhibiting HSV replication in laboratory studies.¹⁷ These alternatives remain relatively niche, though, and acyclovir resistance has not become widespread enough to change first-line prophylaxis strategies.

Why Timing and Duration Still Spark Debate

One area where oncology practice hasn’t fully settled is exactly how long acyclovir prophylaxis should last. For stem cell transplant patients, data support at least a year of prophylaxis, but the spike in VZV reactivation seen after stopping the drug, as pediatric data showed, raises the question of whether some patients need it indefinitely. Some transplant programs continue acyclovir for as long as a patient remains on immunosuppressive therapy for graft-versus-host disease, which can be years.

For patients with blood cancers on chemotherapy, the prophylaxis window typically covers the period of most intense immune suppression, often starting a few days before chemotherapy and continuing until the immune cell counts recover. One trial in acute myeloid leukemia patients gave acyclovir for 28 days from the start of remission-induction chemotherapy.¹⁸ But patients who go on to receive multiple rounds of consolidation chemotherapy, or who need maintenance therapy with immunosuppressive agents, may cycle on and off prophylaxis or stay on it continuously for months.

The challenge is balancing the clear short-term benefit of preventing painful and dangerous herpes reactivations against the low but real risks of long-term antiviral use: kidney stress, the possibility of drug resistance, pill burden, and cost. Most clinicians lean toward longer prophylaxis when the patient is still clearly immunosuppressed, shortening or stopping it only when immune recovery is well underway. Getting that judgment right requires close attention to blood counts, kidney function, and the specific drugs a patient is receiving, which is one reason acyclovir management stays in the hands of oncology and infectious disease specialists rather than being handled as a routine prescription.